Loading stock data…
Agios Pharmaceuticals, Inc. (AGIO)
$33.01-0.09 (-0.29%)
Market OpenUpdated 9:49 AM EDT
Agios Pharmaceuticals, Inc., a biopharmaceutical company, discovers and develops medicines in the field of cellular metabolism in the United States.
Historical Price
Price (Candle)
50-Day SMA
200-Day SMA
Whystock Brain
The Narrative
Agios Pharmaceuticals, Inc. in the Healthcare sector is trading at $33.10 with a market capitalization of $1.9B. Wall Street consensus targets $45.75 (8 analysts), implying a +38.2% move over the next 12 months. The stock is currently 28% below its 52-week high of $46.00, remaining 8.5% above its 200-day moving average. On fundamentals, Piotroski 3/9 flags weak fundamentals, Altman Z in the safe zone. The Whystock Score of 90/100 reflects bullish alignment across trend, valuation and analyst targets.
Ecosystem Influences
Sell-side targets imply +38.2% upside over 12 months
Long-term trend bullish (price vs 200-day SMA)
Macro-economic sensitivity to interest rate and inflation shifts
Quarterly Financials
| Metric (USD) | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 |
|---|---|---|---|---|---|
| Total Revenue | $44.74M↑ | $20.75M↑ | $19.97M↑ | $12.88M↑ | $12.46M |
| Gross Profit | $41.75M↑ | $19.43M↑ | $18.09M↑ | $11.20M↑ | $10.75M |
| Operating Income | -$110.55M↓ | -$110.03M↑ | -$121.58M↓ | -$116.87M↑ | -$127.06M |
| Net Income | -$100.70M↓ | -$99.11M↑ | -$108.04M↓ | -$103.43M↑ | -$112.02M |
Peer Comparison
JNJUNHPFE
Fundamentals
Agios Pharmaceuticals, Inc., a biopharmaceutical company, discovers and develops medicines in the field of cellular metabolism in the United States. Its lead product includes PYRUKYND (mitapivat), an activator of wild-type and mutant pyruvate kinase ...
Market Cap
Total dollar market value of a company's outstanding shares of stock (Price * Shares).
$1.89B
P/E Ratio
Priced for growth. Investors expect sustained double-digit expansion.
-
Beta
Defensive asset. Lower volatility than the S&P 500.
0.59
Div Yield
Low to zero yield. Return is entirely dependent on price appreciation.
0.00%
ROE
Average efficiency. Growth may require heavy reinvestment.
-40.09%
Volume
Today's trading volume
36,678
Recent News
Revolution Medicines (RVMD) Up 6.6% Since Last Earnings Report: Can It Continue?
Revolution Medicines (RVMD) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
AGIO Q2 Earnings Beat Estimates, Revenues Increase Year Over Year
Agios tops Q2 revenue and earnings estimates as Aqvesme's launch and Pyrukynd sales fuel growth, while advancing its hematology pipeline.
Agios Pharmaceuticals Inc (AGIO) (Q2 2026) Earnings Call Highlights: Strong Mitapivat Revenue ...
Agios reports $44.7 million in Q2 mitapivat revenue and FDA priority review for sickle cell disease, while advancing pipeline diversification with cevidoplenib.
Agios Pharmaceuticals Q2 Earnings Call Highlights
Agios Pharmaceuticals (NASDAQ:AGIO) reported second-quarter 2026 mitapivat net revenue of $44.7 million, including $40.9 million in the United States and $3.8 million outside the U.S., as the company continued the U.S. thalassemia launch of AQVESME and prepared for a potential sickle cell disease ap
Agios Pharmaceuticals (AGIO) Reports Q2 Loss, Beats Revenue Estimates
Agios Pharmaceuticals (AGIO) delivered earnings and revenue surprises of +9.14% and +97.29%, respectively, for the quarter ended June 2026. Do the numbers hold clues to what lies ahead for the stock?